If history repeats, investor optimism for NewLink's phase III study is misplaced.
Express Scripts is one of the largest PBM (Pharmacy Benefit Management) companies in the U.S. with over 1.5 billion in administered prescriptions a year. It is an industry bellwether, has a strong new management team and a solid balance sheet. 2013 was a decent year for the company and the stock gained 30% but I think the story gets better in 2014...
Despite the recent volatility in the company's stock, TG Therapeutics cancer drugs are on track for approval and will ultimately fill a niche where old generic chemotherapies have failed.
An investor short Endocyte explains his negative view on the upcoming European approval decision in ovarian cancer and why the lung cancer study is likely to fail.
European markets were largely down Tuesday morning after yesterday's big gains. Jonathan Braude reports from London.
The medical-device maker recently reported disappointing earnings but the stock looks like a buying opportunity for patient investors.
Here's a technical look at five potentially explosive biotech stock plays.
Tenet is facing serious accusations but is determined to meet its objectives.
A just-published academic paper on multi-level marketers supports the notion that the multi-level marketing industry has a serious unresolved issue or two.Before you go dismissing this as just another academic paper, consider the authors: FTC senior economist and pyramid scheme expert, Peter van der Nat and Bill Keep, dean of the business school at The College of New Jersey. In 2002 they co-authored a highly regarded paper explaining what differentiates a legitimate multi-level marketer from a pyramid scheme.In this piece, which doesn't pick on any company in particular, Van der Nat and Keep give an exceptionally well-spelled-out history of multi-level marketers, but then dive into the deep-in-the-weeds legal decisions and "continuing concerns."Perhaps nothing in the paper is more compelling to multi-level marketing aficionados as their discussion of internal consumption. This is when distributors get compensated for sales to themselves and other distributors. A key issue in the debates on Herbalife, Nu Skin and others is how much compensation comes from internal consumption vs. genuine external sales.
A strong showing from U.S. health care players, as well as international customers, supported Qliktech's Q4 Street-beating results, says the company's CEO Lars Bjork.
Girl Scouts are reportedly having wild success selling cookies outside marijuana dispensaries.
Biotech columnist Adam Feuerstein answers readers' questions about health care companies.
Companies in the Barrow All-Cap Core Fund are merger targets four times more than the market at large because the fund's managers take a private equity approach to stock-picking.
I've received so much hate email and tweets over the past week, enough to fill a special edition of the Mailbag.
Rigosertib performed pretty much as expected but the control arm of the study lived longer than anticipated, thereby causing the negative result.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass + 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV